Manifestations and Treatment of Acute Graft-versus-Host Disease

Thomas' Hematopoietic Cell Transplantation: Fifth Edition

Volumn 2-2, Issue , 2016, Pages 1012-1025

  Cutler, Corey ^a   Antin, Joseph H ^b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute graft versus host disease; Corticosteroids; Hematopoietic stem cell source; Human leukocyte antigen; Reduced intensity conditioning

Indexed keywords

EID: 84979928360     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118416426.ch83     Document Type: Chapter

References (284)

1. Mielcarek M, Storb R. Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. Leuk Lymphoma 2005; 46: 1251-1260.
2. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
3. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
4. Weisdorf DJ, Snover DC, Haake R, et al. Acute upper gastrointestinal graft-versushost disease: clinical significance and response to immunosuppressive therapy. Blood 1990; 76: 624-629.
5. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855-864.
6. Cahn JY, Klein JP, Lee SJ, et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005; 106: 1495-1500.
7. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95: 3702-3709.
8. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99: 1943-1951.
9. McGlave PB, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. Blood 2000; 95: 2219-2225.
10. Atkinson K, Horowitz MM, Biggs JC, et al. The clinical diagnosis of acute graft-versus- host disease: a diversity of views amongst marrow transplant centers. Bone Marrow Transplant 1988; 3: 5-10.
11. Weisdorf DJ, Hurd D, Carter S, et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant 2003; 9: 512-518.
12. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464-1472.
13. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765-771.
14. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104: 1923-1930.
15. Shaw BE, Gooley TA, Malkki M, et al. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood 2007; 110: 4560-4566.
16. Woolfrey A, Klein JP, Haagenson M, et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 885-892.
17. Fleischhauer K, Shaw BE, Gooley T, et al. Effect of T-cell-epitope matching at HLADPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol 2012; 13: 366-374.
18. Petersdorf EW, Kollman C, Hurley CK, et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program experience. Blood 2001; 98: 2922-2929.
19. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-4583.
20. Weisdorf D, Hakke R, Blazar B, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991; 51: 1197-1203.
21. Bross DS, Tutschka PJ, Farmer ER, et al. Predictive factors for acute graft-versushost disease in patients transplanted with HLA-identical bone marrow. Blood 1984; 63: 1265-1270.
22. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-1845.
23. Pasquini R, Wang Z. Current Use and Outcome of Hematopoietic Stem Cell Transplantation: CIBMTR Summary Slides, 2011. CIBMTR, http://www.cibmtr.org, 2011 (accessed 6 January 2015).
24. Bacigalupo A, Zikos P, Van Lint M-T, et al. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience. Exp Hematol 1998; 26: 409-414.
25. Russell JA, Larratt L, Brown C, et al. Allogeneic blood stem cells and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome. Bone Marrow Transplant 1999; 24: 1177-1183.
26. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-4709.
27. Üstün C, Arslan ö, Beksaç M, et al. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. Biol Blood Marrow Transplant 1999; 5: 28-35.
28. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
29. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus Lenograstim-primed blood cell allogeneic transplantation in patients with earlystage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol 2000; 18: 537-546.
30. Couban S, Simpson DR, Barnett MJ, et al. A randomized multicentre comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525-1531.
31. Heldal D, Tjonnfjord G, Brinch L, et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000; 25: 1129-1136.
32. Mahmoud H, Fahmy O, Kamel A, et al. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 355-358.
33. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 335: 1231-1237.
34. Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100: 761-767.
35. Vigorito AC, Azevedo WM, Marques JFC, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22: 1145-1151.
36. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a metaanalysis. J Clin Oncol 2001; 19: 3685-3691.
37. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074-5087.
38. Remberger M, Ringden O, Blau IW, et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98: 1739-1745.
39. Ringden O, Remberger M, Runde V, et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999; 94: 455-464.
40. Eapen M. Peripheral blood stem cells versus bone marrow for ablative transplantation. Biol Blood Marrow Transplant 2007; 13(Suppl. 1): 76-77.
41. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487-1496.
42. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
43. Körbling M, Huh YO, Durett A, et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-2848.
44. Mohty M, Bilger K, Jourdan E, et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003; 17: 869-875.
45. Cao TM, Wong RM, Sheehan K, et al. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol 2005; 33: 279-285.
46. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855-864.
47. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005; 366: 733-741.
48. Cao TM, Shizuru JA, Wong RM, et al. Engraftment and survival following reducedintensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood 2005; 105: 2300-2306.
49. Mohty M, Bagattini S, Chabannon C, et al. CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Exp Hematol 2004; 32: 1097-1102.
50. Pabst C, Schirutschke H, Ehninger G, et al. The graft content of donor T cells expressing ?dTCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. Clin Cancer Res 2007; 13: 2916-2922.
51. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLAmatched allogeneic SCT. Blood 2006; 108: 1291-1297.
52. Wolf D, Wolf AM, Fong D, et al. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2007; 83: 1107-1113.
53. Arimoto K, Kadowaki N, Ishikawa T, et al. FOXP3 expression in peripheral blood rapidly recovers and lacks correlation with the occurrence of graft-versus-host disease after allogeneic stem cell transplantation. Int J Hematol 2007; 85: 154-162.
54. Stanzani M, Martins SL, Saliba RM, et al. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLAidentical stem cell transplantation in humans. Blood 2004; 103: 1140-1146.
55. Singhal S, Powles R, Kulkarni S, et al. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs. blood stem cell transplantation. Bone Marrow Transplant 2000; 25: 501-505.
56. Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colonystimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227.
57. Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99: 2726-2733.
58. Ringden O, Barrett AJ, Zhang MJ, et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Hematol 2003; 121: 874-885.
59. Baron F, Maris MB, Storer BE, et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005; 19: 822-828.
60. Kollman C, Klein JP, Spellman SR, et al. The effect of donor characteristics on graft vs. host disease (GVHD) and survival after unrelated donor transplantation for hematologic malignancy [Abstract]. Biol Blood Marrow Transplant 2013; 19: S146-S147.
61. Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012; 119: 296-307.
62. Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995; 15: 663-668.
63. Alousi AM, Le-Rademacher J, Saliba RM, et al. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? Blood 2013; 121: 2567-2573.
64. Flowers ME, Pepe MS, Longton G, et al. Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. Br J Haematol 1990; 74: 492-496.
65. Loren AW, Bunin GR, Boudreau C, et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 758-769.
66. Passweg JR, Zhang MJ, Rocha V, et al. Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies. Biol Blood Marrow Transplant 2011; 17: 1869-1873.
67. Eiz-Vesper B, Seltsam A, Blasczyk R. ABO glycosyltransferases as potential source of minor histocompatibility antigens in allogeneic peripheral blood progenitor cell transplantation. Transfusion 2005; 45: 960-968.
68. Seebach JD, Stussi G, Passweg JR, et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant 2005; 11: 1006-1013.
69. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
70. den Haan JM, Sherman NE, Blokland E, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995; 268: 1476-1480.
71. Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334: 281-285.
72. Martin PJ. How much benefit can be expected from matching for minor antigens in allogeneic marrow transplantation? Bone Marrow Transplant 1997; 20: 97-100.
73. McCarroll SA, Bradner JE, Turpeinen H, et al. Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet 2009; 41: 1341-1344.
74. Morishima Y, Kodera Y, Hirabayashi N, et al. Low incidence of acute GVHD in patients transplanted with marrow from HLA-A,B,DR-compatible unrelated donors among Japanese. Bone Marrow Transplant 1995; 15: 235-239.
75. Klingemann HG, Deeg HJ, Self S, et al. Is race a risk factor for allogeneic marrow transplantation? Bone Marrow Transplant 1986; 1: 87-94.
76. Easaw SJ, Lake DE, Beer M, et al. Graft-versus-host disease. Possible higher risk for African American patients. Cancer 1996; 78: 1492-1497.
77. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996; 335: 369-376.
78. Balduini CL, Noris P, Giorgiani G, et al. Incompatibility for CD31 and human platelet antigens and acute graft-versus-host disease after bone marrow transplantation. Br J Hematol 1999; 106: 723-729.
79. Vogt MH, van den Muijsenberg JW, Goulmy E, et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 2002; 99: 3027-3032.
80. Petersdorf EW, Malkki M, Gooley TA, et al. MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med 2007; 4(1): e8.
81. Chien JW, Zhang XC, Fan W, et al. Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood 2012; 119: 5311-5319.
82. Gagne K, Brizard G, Gueglio B, et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002; 63: 271-280.
83. Schaffer M, Malmberg KJ, Ringden O, et al. Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation 2004; 78: 1081-1085.
84. Kalayoglu-Besisik S, Caliskan Y, Sargin D, et al. Methylenetetrahydrofolate reductase C677T polymorphism and toxicity in allogeneic hematopoietic cell transplantation. Transplantation 2003; 76: 1775-1777.
85. Robien K, Schubert MM, Bruemmer B, et al. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 2004; 22: 1268-1275.
86. Robien K, Bigler J, Yasui Y, et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 2006; 12: 973-980.
87. Bogunia-Kubik K, Lange A. HSP70-hom gene polymorphism in allogeneic hematopoietic stem-cell transplant recipients correlates with the development of acute graft-versus-host disease. Transplantation 2005; 79: 815-820.
88. Holler E, Rogler G, Herfarth H, et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 2004; 104: 889-894.
89. Middleton PG, Cullup H, Dickinson AM, et al. Vitamin D receptor gene polymorphism associates with graft-versus-host disease and survival in HLA-matched sibling allogeneic bone marrow transplantation. Bone Marrow Transplant 2002; 30: 223-228.
90. Middleton PG, Norden J, Cullup H, et al. Oestrogen receptor alpha gene polymorphism associates with occurrence of graft-versus-host disease and reduced survival in HLA-matched sib-allo BMT. Bone Marrow Transplant 2003; 32: 41-47.
91. Rozman P, Karas M, Kosir A, et al. Are human platelet alloantigens (HPA) minor transplantation antigens in clinical bone marrow transplantation? Bone Marrow Transplant 2003; 31: 497-506.
92. Dickinson AM, Middleton PG, Rocha V, et al. Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol 2004; 127: 479-490.
93. Kallianpur AR. Genomic screening and complications of hematopoietic stem cell transplantation: has the time come? Bone Marrow Transplant 2005; 35: 1-16.
94. Socié G, Loiseau P, Tamouza R, et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2001; 72: 699-706.
95. Atkinson K, Storb R, Weiden PL, et al. In vitro tests correlating with presence or absence of graft-vs-host disease in DLA nonidentical canine radiation chimeras: evidence that clonal abortion maintains stable graft-host tolerance. J Immunol 1980; 124: 1808-1814.
96. Fukushi N, Arase H, Wang B, et al. Thymus: a direct target tissue in graft-versus- host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance. Proc Natl Acad Sci U S A 1990; 87: 6301-6305.
97. Rosenkrantz K, Keever C, Bhimani K, et al. Both ongoing suppression and clonal elimination contribute to graft-host tolerance after transplantation of HLA mismatched T cell-depleted marrow for severe combined immunodeficiency. J Immunol 1990; 144: 1721-1728.
98. Trenado A, Sudres M, Tang Q, et al. Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol 2006; 176: 1266-1273.
99. Teshima T, Matsuoka K, Ichinohe T. Impact of fetal-maternal tolerance in hematopoietic stem cell transplantation. Arch Immunol Ther Exp (Warsz) 2006; 54: 165-172.
100. Matsuoka K, Ichinohe T, Hashimoto D, et al. Fetal tolerance to maternal antigens improves the outcome of allogeneic bone marrow transplantation by a CD4+ CD25+ T-cell-dependent mechanism. Blood 2006; 107: 404-409.
101. Ichinohe T, Teshima T, Matsuoka K, et al. Fetal-maternal microchimerism: impact on hematopoietic stem cell transplantation. Curr Opin Immunol 2005; 17: 546-552.
102. van Rood JJ, Loberiza FR, Jr., Zhang MJ, et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood 2002; 99: 1572-1577.
103. Rocha V, Spellman S, Zhang MJ, et al. Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2012; 18: 1890-1896.
104. Scaradavou A. HLA-mismatched, noninherited maternal antigen-matched unrelated cord blood transplantations have superior survival: how HLA typing the cord blood donor's mother can move the field forward. Biol Blood Marrow Transplant 2012; 18: 1773-1775.
105. Perez-Simon JA, Diez-Campelo M, Martino R, et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Hematol 2005; 130: 394-403.
106. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-2312.
107. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867-1871.
108. Hill RS, Petersen FB, Storb R, et al. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 1986; 67: 811-816.
109. Petz LD, Yam P, Wallace RB, et al. Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies. Blood 1987; 70: 1331-1337.
110. van Bekkum DW, Roodenburg J, Heidt PJ, van der WD. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974; 52: 401-404.
111. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983; 308: 302-307.
112. Beelen DW, Elmaagacli A, Muller KD, et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93: 3267-3275.
113. Trenschel R, Peceny R, Runde V, et al. Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination. Bone Marrow Transplant 2000; 26: 993-997.
114. Grundy JE, Shanley JD, Shearer GM. Augmentation of graft-versus-host reaction by cytomegalovirus infection resulting in interstitial pneumonitis. Transplantation 1985; 39: 548-553.
115. Murphy S, Nguyen VH. Role of gut microbiota in graft-versus-host disease. Leuk Lymphoma 2011; 52: 1844-1856.
116. Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 2012; 209: 903-911.
117. Eriguchi Y, Takashima S, Oka H, et al. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of alpha-defensins. Blood 2012; 120: 223-231.
118. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versushost disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 107: 1581-1589.
119. Cooke KR, Olkiewicz K, Erickson N, Ferrara JL. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J Endotoxin Res 2002; 8: 441-448.
120. Petersen FB, Buckner CD, Clift RA, et al. Laminar air flow isolation and decontamination: a prospective randomized study of the effects of prophylactic systemic antibiotics in bone marrow transplant patients. Infection 1986; 14: 115-121.
121. Beelen DW, Haralambie E, Brandt H, et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 1992; 80: 2668-2676.
122. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebocontrolled trial. Blood 2000; 96: 2055-2061.
123. Krijanovski OI, Hill GR, Cooke KR, et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 1999; 94: 825-831.
124. Levine JE, Blazar BR, Defor T, et al. Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant 2008; 14: 1017-1021.
125. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
126. Saurat JH. Cutaneous manifestations of graft-versus-host disease. Int J Dermatol 1981; 20: 249-256.
127. Sale GE, Shulman HM, Gallucci BB, Thomas ED. Young rete ridge keratinocytes are preferred targets in cutaneous graft-versus-host disease. Am J Pathol 1985; 118: 278-287.
128. Roy J, Snover D, Weisdorf S, et al. Simultaneous upper and lower endoscopic biopsy in the diagnosis of intestinal graft-versus-host disease. Transplantation 1991; 51: 642-646.
129. Melin-Aldana H, Thormann K, Duerst R, et al. Hepatitic pattern of graft versus host disease in children. Pediatr Blood Cancer 2007; 49: 727-730.
130. Mullighan CG, Bogdanos DP, Vergani D, Bardy PG. Cytochrome P450 1A2 is a target antigen in hepatitic graft-versus-host disease. Bone Marrow Transplant 2006; 38: 703-705.
131. Ma SY, Au WY, Ng IO, et al. Hepatitic graft-versus-host disease after hematopoietic stem cell transplantation: clinicopathologic features and prognostic implication. Transplantation 2004; 77: 1252-1259.
132. Akpek G, Boitnott JK, Lee LA, et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 2002; 100: 3903-3907.
133. Malik AH, Collins RH, Jr., Saboorian MH, Lee WM. Chronic graft-versus-host disease after hematopoietic cell transplantation presenting as an acute hepatitis. Am J Gastroenterol 2001; 96: 588-590.
134. Saito T, Shinagawa K, Takenaka K, et al. Ocular manifestation of acute graft-versus- host disease after allogeneic peripheral blood stem cell transplantation. Int J Hematol 2002; 75: 332-334.
135. Jack MK, Jack GM, Sale GE, et al. Ocular manifestations of graft-v-host disease. Arch Ophthalmol 1983; 101: 1080-1084.
136. Jabs DA, Wingard J, Green WR, et al. The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. Arch Ophthalmol 1989; 107: 1343-1348.
137. Kim RY, Anderlini P, Naderi AA, et al. Scleritis as the initial clinical manifestation of graft-versus-host disease after allogenic bone marrow transplantation. Am J Ophthalmol 2002; 133: 843-845.
138. Lockman LA, Sung JH, Krivit W. Acute parkinsonian syndrome with demyelinating leukoencephalopathy in bone marrow transplant recipients. Pediatr Neurol 1991; 7: 457-463.
139. Provenzale JM, Graham ML. Reversible leukoencephalopathy associated with graft-versus-host disease: MR findings. AJNR Am J Neuroradiol 1996; 17: 1290-1294.
140. Majhail NS, Parks K, Defor TE, Weisdorf DJ. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant 2006; 12: 1038-1046.
141. Cutler C, Henry N, Magee C, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 551-557.
142. Holler E, Kolb HJ, Hiller E, et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 1989; 73: 2018-2024.
143. Anasetti C, Rybka W, Sullivan KM, et al. Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood 1989; 73: 1054-1058.
144. Bruno B, Gooley T, Sullivan KM, et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 154-162.
145. Kim DH, Sohn SK, Jeon SB, et al. Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD. Bone Marrow Transplant 2006; 37: 101-108.
146. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 893-898.
147. Firoz BF, Lee SJ, Nghiem P, Qureshi AA. Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis. Arch Dermatol 2006; 142: 175-182.
148. Kohler S, Hendrickson MR, Chao NJ, Smoller BR. Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. Am J Surg Pathol 1997; 21: 988-996.
149. Zhou Y, Barnett MJ, Rivers JK. Clinical significance of skin biopsies in the diagnosis and management of graft-vs-host disease in early postallogeneic bone marrow transplantation. Arch Dermatol 2000; 136: 717-721.
150. Ferrara JL. Novel strategies for the treatment and diagnosis of graft-versus-hostdisease. Best Pract Res Clin Haematol 2007; 20: 91-97.
151. Jordan WJ, Brookes PA, Szydlo RM, et al. IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation. Blood 2004; 103: 717-724.
152. Miyamoto T, Akashi K, Hayashi S, et al. Serum concentration of the soluble interleukin- 2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant 1996; 17: 185-190.
153. Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood 2013; 121: 585-594.
154. Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012; 119: 3854-3860.
155. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graftversus- host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024-1030.
156. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387-394.
157. Levine JE, Logan B, Wu J, et al. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant 2010; 16: 1693-1699.
158. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood 2010; 115: 5412-5417.
159. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versushost disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92: 2288-2293.
160. Leisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006; 108: 749-755.
161. Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981; 11: 1-8.
162. Deeg HJ. How I treat refractory acute GVHD. Blood 2007; 109: 4119-4126.
163. Bacigalupo A. Management of acute graft-versus-host disease. Br J Hematol 2007; 137: 87-98.
164. Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009; 113: 2888-2894.
165. Hings IM, Filipovich AH, Miller WJ, et al. Prednisone therapy for acute graftversus- host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation 1993; 56: 577-580.
166. Cragg L, Blazar BR, Defor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6: 441-447.
167. Dugan MJ, DeFor TE, Steinbuch M, et al. ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival. Ann Hematol 1997; 75: 41-46.
168. Graziani F, Van Lint MT, Dominietto A, et al. Treatment of acute graft versus host disease with low dose-alternate day anti-thymocyte globulin. Haematologica 2002; 87: 973-978.
169. Lee SJ, Zahrieh D, Agura E, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004; 104: 1559-1564.
170. Cahn JY, Bordigoni P, Tiberghien P, et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 1995; 60: 939-942.
171. Martin PJ, Nelson BJ, Appelbaum FR, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996; 88: 824-830.
172. Couriel DR, Saliba R, de Lima M, et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 1555-1562.
173. Hockenbery DM, Cruickshank S, Rodell TC, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007; 109: 4557-4563.
174. Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009; 114: 511-517.
175. Bolaños-Meade J, Logan BR, Alousi AM, et al. A multi-center, randomized, double blind, phase III clinical trial comparing steroids/placebo vs. steroids/mycophenolate mofetil as initial therapy for acute graft-versus-host disease. Blood and Marrow Transplant Clinical Trials Network Study 0802 [Abstract]. Biol Blood Marrow Transplant 2013; 19: S137.
176. Hsu B, May R, Carrum G, et al. Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transplant 2001; 28: 945-950.
177. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77: 1821-1828.
178. Arai S, Margolis J, Zahurak M, et al. Poor outcome in steroid-refractory graft-versus- host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155-160.
179. Khoury H, Kashyap A, Adkins DR, et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001; 27: 1059-1064.
180. Remberger M, Aschan J, Barkholt L, et al. Treatment of severe acute graft-versushost disease with anti-thymocyte globulin. Clin Transplant 2001; 15: 147-153.
181. MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 40-46.
182. Knop S, Hebart H, Gscheidle H, et al. OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. Bone Marrow Transplant 2005; 36: 831-837.
183. Knop S, Hebart H, Gratwohl A, et al. Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party. Leukemia 2007; 21: 1830-1833.
184. Martin PJ, Shulman HM, Schubach WH, et al. Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Ann Intern Med 1984; 101: 310-315.
185. Carpenter PA, Lowder J, Johnston L, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 465-471.
186. Jackson K, Curley C, Leach J, et al. Alemtuzumab as salvage therapy for steroid and ATG/etanercept-refractory acute GVHD. Bone Marrow Transplant 2011; 46: 1579-1580.
187. Gómez-Almaguer D, Ruiz-Argüelles GJ, del Carmen Tarín-Arzaga, et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14: 10-15.
188. Martinez C, Solano C, Ferra C, et al. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study. Biol Blood Marrow Transplant 2009; 15: 639-642.
189. Anasetti C, Martin PJ, Hansen JA, et al. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation 1990; 50: 49-54.
190. Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac+ cells. J Immunol 1981; 126: 1393-1397.
191. Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J Immunol 1981; 126: 1398-1403.
192. Bay JO, Dhedin N, Goerner M, et al. Inolimomab in steroid-refractory acute graftversus- host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation 2005; 80: 782-788.
193. Cuthbert RJ, Phillips GL, Barnett MJ, et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplant 1992; 10: 451-455.
194. García-Cadenas I, Valcárcel D, Martino R, et al. Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2013; 19: 435-439.
195. Massenkeil G, Rackwitz S, Genvresse I, et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 899-903.
196. Schmidt-Hieber M, Fietz T, Knauf W, et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Hematol 2005; 130: 568-574.
197. Funke VA, de Medeiros CR, Setubal DC, et al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant 2006; 37: 961-965.
198. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994; 84: 1320-1327.
199. Perales MA, Ishill N, Lomazow WA, et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant 2007; 40: 481-486.
200. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin- 2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83-89.
201. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 1989; 86: 10029-10033.
202. Willenbacher W, Basara N, Blau IW, et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001; 112: 820-823.
203. Ho VT, Zahrieh D, Hochberg E, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 1224-1226.
204. Shaughnessy PJ, Bachier C, Grimley M, et al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 188-193.
205. Deeg HJ, Blazar BR, Bolwell BJ, et al. Treatment of steroid-refractory acute graftversus- host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 2001; 98: 2052-2058.
206. MacMillan ML, Couriel D, Weisdorf DJ, et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroidresistant acute graft-versus-host disease. Blood 2007; 109: 2657-2662.
207. Busca A, Locatelli F, Marmont F, et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versushost disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007; 82: 45-52.
208. Kobbe G, Schneider P, Rohr U, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001; 28: 47-49.
209. Jacobsohn DA, Hallick J, Anders V, et al. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 2003; 74: 119-124.
210. Herve P, Flesch M, Tiberghien P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graftversus- host disease. Blood 1992; 79: 3362-3368.
211. Patriarca F, Sperotto A, Damiani D, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004; 89: 1352-1359.
212. Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004; 104: 649-654.
213. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graftversus- host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768-2776.
214. Kennedy GA, Butler J, Western R, et al. Combination antithymocyte globulin and soluble TNFa inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant 2006; 37: 1143-1147.
215. Rager A, Frey N, Goldstein SC, et al. Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD. Bone Marrow Transplant 2011; 46: 430-435.
216. Rao K, Rao A, Karlsson H, et al. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroidrefractory graft-versus-host disease. J Pediatr Hematol Oncol 2009; 31: 456-461.
217. Rodriguez V, Anderson PM, Trotz BA, et al. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. Pediatr Blood Cancer 2007; 49: 212-215.
218. Wolff D, Roessler V, Steiner B, et al. Treatment of steroid-resistant acute graftversus- host disease with daclizumab and etanercept. Bone Marrow Transplant 2005; 35: 1003-1010.
219. Bolaños-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005; 23: 2661-2668.
220. Schmitt T, Luft T, Hegenbart U, et al. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis. Bone Marrow Transplant 2011; 46: 580-585.
221. Pidala J, Kim J, Roman-Diaz J, et al. Pentostatin as rescue therapy for glucocorticoid- refractory acute and chronic graft-versus-host disease. AnnTransplant 2010; 15: 21-29.
222. Furlong T, Martin P, Flowers ME, et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant 2009; 44: 739-748.
223. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348.
224. Benito AI, Furlong T, Martin PJ, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72: 1924-1929.
225. Hoda D, Pidala J, Salgado-Vila N, et al. Sirolimus for treatment of steroidrefractory acute graft-versus-host disease. Bone Marrow Transplant 2010; 45: 1347-1351.
226. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 7-12.
227. Biagi E, Di Biaso I, Leoni V, et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 2007; 84: 31-39.
228. Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96: 2426-2431.
229. Perfetti P, Carlier P, Strada P, et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008; 42: 609-617.
230. Wetzig T, Sticherling M, Simon JC, et al. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant 2005; 35: 515-519.
231. Wiesmann A, Weller A, Lischka G, et al. Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study. Bone Marrow Transplant 1999; 23: 151-155.
232. Furlong T, Leisenring W, Storb R, et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 206-212.
233. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 321-334.
234. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graftversus- host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441.
235. Martin PJ, Uberti JP, Soiffer RJ, et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD [Abstract]. Biol Blood Marrow Transplant 2010; 16: S169-S170.
236. Tfayli A, Selby G, Maqbool F,et al. Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. Am J Hematol 2006; 81: 959-962.
237. Sato T, Sakamaki S, Nagaoka Y, et al. Intra-mesenteric artery steroid administration relieved severe refractory gastro-intestinal graft-vs.-host disease in an allogeneic bone marrow transplantation patient. Am J Hematol 1997; 56: 277-280.
238. Shapira MY, Bloom AI, Or R, et al. Intra-arterial catheter directed therapy for severe graft-versus-host disease. Br J Hematol 2002; 119: 760-764.
239. Bloom AI, Shapira MY, Or R, et al. Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial. Clin Ther 2004; 26: 407-414.
240. Shapira MY, Resnick IB, Bitan M, et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant 2005; 36: 1097-1101.
241. Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84: 1342-1348.
242. Bianco JA, Higano C, Singer J, et al. The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation. Transplantation 1990; 49: 1194-1195.
243. Ippoliti C, Champlin R, Bugazia N, et al. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol 1997; 15: 3350-3354.
244. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.
245. Tanaka Y, Kami M, Ogawa S, et al. Hyperacute graft-versus-host disease and NKT cells. Am J Hematol 2000; 63: 60-61.
246. Saliba RM, de Lima M, Giralt S, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 2007; 109: 2751-2758.
247. Kim DH, Sohn SK, Kim JG, et al. Clinical impact of hyperacute graft-versus-host disease on results of allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 33: 1025-1030.
248. Davies SM, Weisdorf DJ, Haake RJ, et al. Second infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14: 73-77.
249. Sullivan KM, Deeg HJ, Sanders J, et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 1986; 67: 1172-1175.
250. Hess AD. Autologous graft-versus-host disease. J Hematother Stem Cell Res 2000; 9: 297.
251. Santos GW. Autologous graft-versus-host disease. Leukemia 1992; 6(Suppl. 4): 110-111.
252. Zenz T, Ritgen M, Dreger P, et al. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 108: 2127-2130.
253. Miura Y, Thoburn CJ, Bright EC, Hess AD. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand. Biol Blood Marrow Transplant 2004; 10: 156-170.
254. Giralt S, Weber D, Colome M, et al. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol. 1997; 15: 667-673.
255. Pati AR, Godder KT, Abhyankar SH, et al. Cyclosporine-induced autologous graft-versus-host disease following autologous blood stem cell transplantation for lymphoma. Bone Marrow Transplant 1996; 17: 1081-1083.
256. Yeager AM, Vogelsang GB, Jones RJ, et al. Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation for acute myeloid leukemia. Leuk Lymphoma 1993; 11: 215-220.
257. Holmberg L, Kikuchi K, Gooley TA, et al. Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2006; 12: 226-234.
258. Saunders MD, Shulman HM, Murakami CS, et al. Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation. Am J Surg Pathol 2000; 24: 1004-1008.
259. Yeager AM, Vogelsang GB, Jones RJ, et al. Induction of cutaneous graft-versushost disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 79: 3031-3035.
260. Greenbaum BH. Transfusion-associated graft-versus-host disease: historical perspectives, incidence, and current use of irradiated blood products. J Clin Oncol 1991; 9: 1889-1902.
261. Parkman R, Mosier D, Umansky I, et al. Graft-versus-host disease after intrauterine and exchange transfusions for hemolytic disease of the newborn. N Engl J Med 1974; 290: 359-363.
262. Schroeder ML. Transfusion-associated graft-versus-host disease. Br J Hematol 2002; 117: 275-287.
263. Weiden PL, Zuckerman N, Hansen JA, et al. Fatal graft-versus-host disease in a patient with lymphoblastic leukemia following normal granulocyte transfusion. Blood 1981; 57: 328-332.
264. Nishimura M, Uchida S, Mitsunaga S, et al. Identification of HLA class II antigens as the targets of effector clones which may cause transfusion-associated graft-versus- host disease. Transfus Med 1997; 7: 89-94.
265. Nishimura M, Uchida S, Mitsunaga S, et al. Characterization of T-cell clones derived from peripheral blood lymphocytes of a patient with transfusion-associated graft-versus-host disease: Fas-mediated killing by CD4+ and CD8+ cytotoxic T-cell clones and tumor necrosis factor beta production by CD4+ T-cell clones. Blood 1997; 89: 1440-1445.
266. Juji T, Takahashi K, Shibata Y, et al. Post-transfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan [Letter]. N Engl J Med 1989; 321: 56.
267. Capon SM, DePond WD, Tyan DB, et al. Transfusion-associated graft-versushost disease in an immunocompetent patient. Ann Intern Med 1991; 114: 1025-1026.
268. Kruskall M, Alpher C, Awdeh Z. HLA-homozygous donors and transfusion-associated graft-versus-host disease. N Engl J Med 1990; 322: 1004-1007.
269. Shivdasani RA, Haluska FG, Dock NL, et al. Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med 1993; 328: 766-770.
270. Thomas ED, Herman EC, Jr., Greenough WB, III, et al. Irradiation and marrow infusion in leukemia. Observations in five patients with acute leukemia treated by whole-body exposures of 1,400 to 2,000 roentgens and infusions of marrow. Arch Intern Med 1961; 107: 829-845.
271. Button LN, DeWolf WC, Newburger PE, et al. The effects of irradiation on blood components. Transfusion 1981; 21: 419-426.
272. Anderson KC, Goodnough LT, Sayers M, et al. Variation in blood component irradiation practice: implications for prevention of transfusion-associated graft-versus- host disease. Blood 1991; 77: 2096-2102.
273. Drobyski W, Thibodeau S, Truitt RL, et al. Third-party-mediated graft rejection and graft-versus-host disease after T-cell-depleted bone marrow transplantation, as demonstrated by hypervariable DNA probes and HLA-DR polymorphism. Blood 1989; 74: 2285-2294.
274. Moroff G, Luban NL. The irradiation of blood and blood components to prevent graft-versus-host disease: technical issues and guidelines. Transfus Med Rev 1997; 11: 15-26.
275. American Association of Blood Banks. AABB Technical Manual, 18th edn. Bethesda, MD: AABB, 2014.
276. American Association of Blood Banks. Standards for Blood Banks and Transfusion Services, 29th edn. Bethesda, MD: AABB, 2014.
277. Pelszynski MM, Moroff G, Luban NL, et al. Effect of gamma irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: implications for preventing transfusion-associated graft-versus-host disease. Blood 1994; 83: 1683-1689.
278. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus- host disease by photochemical treatment. Blood 1999; 93: 3140-3147.
279. Fast LD. Developments in the prevention of transfusion-associated graft-versushost disease. Br J Haematol 2012; 158: 563-568.
280. Akahoshi M, Takanashi M, Masuda M, et al. A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters. Transfusion 1992; 32: 169-172.
281. Hayashi H, Nishiuchi T, Tamura H, Takeda K. Transfusion-associated graft-versus- host disease caused by leukocyte-filtered stored blood. Anesthesiology 1993; 79: 1419-1421.
282. Prince M, Szer J, van der Weyden MB, et al. Transfusion associated graft-versushost disease after cardiac surgery: response to antithymocyte-globulin and corticosteroid therapy. Aust N Z.J Med 1991; 21: 43-46.
283. Cohen D, Weinstein H, Mihm M, Yankee R. Nonfatal graft-versus-host disease occurring after transfusion with leukocytes and platelets obtained from normal donors. Blood 1979; 53: 1053-1057.
284. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.